Back to top
more

Enzo Biochem (ENZ)

(Delayed Data from NYSE)

$1.16 USD

1.16
87,843

+0.05 (4.50%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $1.16 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Strongbridge Biopharma (SBBP) Rises: Stock Moves 17% Higher

by Zacks Equity Research

Strongbridge Biopharma plc (SBBP) shares rose almost 17% in the last trading session.

    Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise

    by Zacks Equity Research

    Dr. Reddy's Laboratories Ltd.'s (RDY) first-quarter fiscal 2018 earnings per American Depositary Share (ADS) declined year over year while sales increased from the year ago quarter.

      Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line

      by Zacks Equity Research

      Acorda's (ACOR) dismal performance in Q2 significantly misses earnings expectations. However, the company's revenues met estimates on the back of strong Ampyra sales.

        Keryx (KERX) Posts Wider than Expected Loss in Q2, Sales Beat

        by Zacks Equity Research

        Keryx's (KERX) loss in Q2 was wider than expected but sales beat estimates. The company also raised its 2017 outlook for net U.S. Auryxia product sales.

          Alkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat

          by Zacks Equity Research

          Alkermes plc (ALKS) incurred narrower than expected loss in Q2 but marginally surpassed sales estimates. The company reiterated its 2017 outlook.

            Bayer (BAYRY) Q2 Earnings Beat, Sales Miss, Cuts Guidance

            by Zacks Equity Research

            Bayer AG (BAYRY) topped earnings but missed sales expectations in Q2. The company also lowered its guidance for full-year 2017.

              GlaxoSmithKline (GSK) Beats on Q2 Earnings, Lowers Guidance

              by Zacks Equity Research

              Glaxo's (GSK) second-quarter earnings beat estimates, while revenues miss the same. The company cuts its core 2017 earnings growth at CER, with no Advair generics launched this year.

                Alexion (ALXN) Tops Q2 Earnings & Revenues, Ups 2017 View

                by Zacks Equity Research

                Alexion Pharmaceuticals, Inc. (ALXN) exceeded both earnings and revenue estimates in Q2 and also raised its 2017 guidance.

                  Ironwood (IRWD) Reports Positive Data on Reflux Candidate

                  by Zacks Equity Research

                  Ironwood's GI candidate met the primary endpoint of a phase IIb study. It showed significant reduction in weekly heartburn severity in adult patients with reflux disease.

                    Galapagos (GLPG) Looks Good: Stock Adds 6.2% in Session

                    by Zacks Equity Research

                    Galapagos (GLPG) was a big mover last session, as the company saw its shares rise over 6% on the day.

                      Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab

                      by Zacks Equity Research

                      Emergent's shares inched up post announcement of its deal inked with GlaxoSmithKline to acquire the latter's anthrax monoclonal antibody raxibacumab.

                        Sarepta & BioMarin Settle Patent Litigation on Exon Skipping

                        by Zacks Equity Research

                        Sarepta Therapeutics, Inc. (SRPT), and BioMarin Pharmaceutical Inc., have settled their ongoing global patent litigation pertaining to exon skipping technology used in Duchenne muscular dystrophy therapies.

                          Vertex (VRTX) Triple Combination CF Studies Data Positive

                          by Zacks Equity Research

                          Vertex announced positive data from three studies evaluating three different triple combination regimens. These demonstrated pronounced improvements in lung function in CF patients.

                            Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt

                            by Zacks Equity Research

                            Valeant (VRX) has decided to sell Obagi Medical for $190 million and use the proceeds for reducing down debt.

                              Repros' Proellex Stays on Partial Clinical Hold, Shares Fall

                              by Zacks Equity Research

                              Repros Therapeutics Inc. (RPRX) announced that its pipeline candidate Proellex which is being evaluated for uterine fibroids will remain on partial clinical hold.

                                Arena Announces Secondary Stock Worth $150M (revised)

                                by Zacks Equity Research

                                Arena plans to offer and sell shares of its common stock worth $150 million, subject to customary closing conditions.

                                  Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit

                                  by Zacks Equity Research

                                  Emergent BioSolutions Inc. (EBS) announced that it has inked an agreement to acquire the FDA-licensed smallpox vaccine's business of Sanofi (SNY) in an all-cash deal of up to $125 million.

                                    Can Enzo Biochem (ENZ) Run Higher on Strong Earnings Estimate Revisions?

                                    by Zacks Equity Research

                                    Enzo Biochem (ENZ) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.

                                      Gemphire Therapeutics (GEMP) Catches Eye: Stock Gains 9.7%

                                      by Zacks Equity Research

                                      Gemphire Therapeutics Inc. (GEMP) moved big last session, as its shares rose over 9% on the day.

                                        BioDelivery-Purdue Pharma Ink Marketing Deal for Pain Drug

                                        by Zacks Equity Research

                                        BioDelivery Sciences International, Inc. (BDSI) announced an exclusive partnership agreement with Purdue Pharma, a Canadian pharmaceutical company, for commercializing its pain drug Belbuca in Canada.

                                          Mallinckrodt's MNK-1411 Gets Orphan Drug Status for DMD

                                          by Zacks Equity Research

                                          Mallinckrodt plc (MNK) announced that the FDA has granted orphan drug designation to its pipeline candidate - MNK-1411, which is being evaluated for the treatment of Duchenne muscular dystrophy (DMD).

                                            Corcept Therapeutics Focuses on Korlym's Label Expansion

                                            by Zacks Equity Research

                                            We issued an updated research report on Corcept Therapeutics Incorporated (CORT) on Jul 12.

                                              Endocyte (ECYT) to Focus on Promising CAR-T Cell Platform

                                              by Zacks Equity Research

                                              We issued an updated research report Endocyte, Inc. (ECYT) on Jul 12.

                                                Mallinckrodt to Pay $35M for Controlled Substances Probe

                                                by Zacks Equity Research

                                                Mallinckrodt plc (MNK) recently finalized the agreement which it had reached with the U.S. Drug Enforcement Administration (DEA) and the U.S. Attorneys' Offices (USAOs) for the Eastern District of Michigan and the Northern District of New York.

                                                  Arena Announces Secondary Stock Offering of 150M Shares

                                                  by Zacks Equity Research

                                                  Arena Pharmaceuticals, Inc. (ARNA) plans to offer and sell 150 million shares of its common stock, subject to customary closing conditions.